After baseline testing, WT mice underwent a right distal tibia fracture (FX) and the hindlimb was casted for 3 weeks, then the cast was removed and the next day the animals retested (n = 12 per cohort). Then the FX mice were either subcutaneously injected with the IL-6 receptor antagonist TB-2-081 (FX + TB-2-081, n = 8) or vehicle (FX + Vehicle, n = 6). A control cohort of WT mice did not undergo tibia fracture (Control, n = 12). At 15 minutes post-injection the mice were retested. The IL-6 receptor antagonist partially inhibited the development of von Frey allodynia (A) and hindlimb unweighting (B) in the fracture mice, when compared to the extent of allodynia and unweighting observed in the vehicle injected mice after fracture. The IL-6 receptor antagonist failed to reverse the hindpaw warmth (C) and edema (D) that was observed in the vehicle injected fracture mice. ***P < 0.001 vs Control, ##P < 0.01, and ###P < 0.001 vs FX + Vehicle.